摘要
目的探讨瑞舒伐他汀对急性冠脉综合征行经皮冠状动脉介入(PCI)治疗患者心功能的影响。方法选取700例急性冠脉综合征患者。随机分成观察组和对照组各60例。所有患者均接受PCI治疗,对照组患者在PCI治疗的基础上给予常规抗血小板、抗凝、扩血管治疗,观察组患者则在对照组的基础上给予瑞舒伐他汀强化治疗。比较2组患者治疗前后的心功能状况、心肌损伤情况、血清炎症因子水平及不良心血管事件发生率。结果 2组患者治疗后左室射血分数(LVEF)显著提高,且观察组显著高于对照组(P<0.05);2组患者治疗后的左心室舒张末期内径(LVDD)以及左心室收缩末期内径(LVSD)显著下降,且观察组显著低于对照组(P<0.05);2组患者治疗后的肌酸激酶同工酶(CK-MB)和心肌肌钙蛋(c Tnl)均显著提高,且观察组显著高于对照组(P<0.05);2组患者治疗后的超敏C反应蛋白(hs-CRP)和脑尿钠肽(BNP)水平均显著下降,且观察组显著低于对照组(P<0.05);观察组患者心脏不良事件和再狭窄的发生率显著均低于对照组患者(P<0.05)。结论瑞舒伐他汀可保护急性冠脉综合征行PCI治疗的患者的心功能,减轻心肌损伤和炎症水平,降低术后心脏不良事件、再狭窄的发生率。
Objective To explore the effect of rosuvastatin on cardiac function of patients with acute coronary syndrome treated by percutaneous coronary intervention(PCI).Methods Totally 700 patients with acute coronary syndrome were selected and randomly divided into observation group and control group,60 cases in each group.All the patients were treated with PCI.On this basis,the control group was treated with conventional anti-platelet,anticoagulation,vasodilator treatment,while the observation group was treated with rosuvastatin on the basis of control group.The cardiac function status,myocardial injury,serum inflammatory cytokine levels and the incidence of adverse cardiovascular events before and after treatment were compared between the two groups.Results The LVEF in both groups significantly improved after treatment,and LVEF in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the LVSD and LVDD significantly decreased in both groups,and these indexes in the observation group were significantly lower than the control group(P<0.05).After treatment,CK-MB and cTnl significantly improved in both groups,and CK-MB and cTnl in the observation group were significantly higher than the control group(P<0.05).The levels of hs-CRP and BNP in both groups significantly decreased after treatment,and these indexes in the observation group were significantly lower than control group(P<0.05).The incidence rates of cardiac adverse events and restenosis were significantly lower in the observation group than the control group(P<0.05).Conclusion Rosuvastatin can protect cardiac function of patients with acute coronary syndrome treated by PCI,reduce myocardial injury and inflammation,and reduce the incidence rates of postoperative cardiac adverse events and restenosis.
作者
李艳
刘宇
LI Yan;LIU Yu(Yanggu County People′s Hospital,Yanggu,Shandong,252300)
出处
《实用临床医药杂志》
CAS
2018年第7期27-30,共4页
Journal of Clinical Medicine in Practice
关键词
急性冠脉综合征
经皮冠状动脉介入
心功能
瑞舒伐他汀
acute coronary syndrome
percutaneous coronary intervention
cardiac function
rosuvastatin
